科研动态PubMed 摘要

人工智能能否提高精准给药?对窄治疗指数药物的系统评价。

PubMed 学科轮询 · 2026-08-17

完整摘要 · 中文译文

背景:由于显著的个体间变异以及治疗有效性与毒性之间的狭窄 margin,窄治疗指数药物的精准给药仍然具有挑战性。基于人工智能(AI)的方法可能通过整合复杂的临床和药物基因组学数据来改善个体化给药。本系统综述评估了基于AI的方法在窄治疗指数药物精准给药中的预测性能和应用。 方法:按照PRISMA指南进行了系统综述。检索了PubMed、Scopus、Cochrane Library和IEEE Xplore从建库至2025年12月的文献,以寻找评估基于AI的方法用于窄治疗指数药物精准给药的研究。符合条件的研究包括评估AI引导给药模型的预测性能或临床结局的临床研究。方法学质量和报告完整性分别使用PROBAST和TRIPOD工具进行评估。 结果:共纳入2018年至2025年间发表的16项研究,大多数聚焦于华法林(n = 8)和他克莫司(n = 5)。集成学习方法,包括随机森林、XGBoost、极端随机树回归器、启发式堆叠和深度森林模型,与常规方法相比经常表现出良好的预测性能。药物基因组学变量,特别是华法林相关的CYP2C9和VKORC1以及他克莫司相关的CYP3A5, consistently被确定为重要预测因素。所识别的AI应用主要与个体化剂量处方相关 以及抗凝药、免疫抑制剂和抗癫痫药物治疗中的预测与治疗药物监测。然而,在人工智能方法学、目标结局、验证策略和报告的性能指标方面观察到显著异质性。大多数研究为回顾性、单中心研究,而外部验证和具有临床意义结局的评估仍然有限。 结论:基于人工智能的方法在改善窄治疗指数药物的精准给药方面显示出有前景的潜力,尤其是在整合药物基因组学和临床变量时。然而,当前证据受到方法学异质性、报告不一致和外部验证不足的限制。在推荐广泛临床实施之前,需要进一步开展评估真实世界临床结局的前瞻性多中心研究。

完整摘要 · 英文原文

BACKGROUND: Precision dosing of narrow therapeutic index drugs remains challenging because of substantial interindividual variability and the narrow margin between therapeutic efficacy and toxicity. Artificial intelligence (AI)-based approaches may improve individualized dosing by integrating complex clinical and pharmacogenomic data. This systematic review evaluated the predictive performance and applications of AI-based approaches for precision dosing in narrow therapeutic index drugs. METHODS: A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, Cochrane Library, and IEEE Xplore were searched from inception to December 2025 for studies evaluating AI-based approaches for precision dosing of narrow therapeutic index drugs. Eligible studies included clinical investigations assessing predictive performance or clinical outcomes of AI-guided dosing models. Methodological quality and reporting completeness were evaluated using the PROBAST and TRIPOD tools, respectively. RESULTS: Sixteen studies published between 2018 and 2025 were included, with most focusing on warfarin (n = 8) and tacrolimus (n = 5). Ensemble learning approaches, including random forest, XGBoost, extra trees regressor, heuristic stacking, and deep forest models, frequently demonstrated favorable predictive performance compared with conventional methods. Pharmacogenomic variables, particularly CYP2C9 and VKORC1 for warfarin and CYP3A5 for tacrolimus, were consistently identified as important predictors. The identified AI applications were primarily related to individualized dose prediction and therapeutic drug monitoring across anticoagulant, immunosuppressant, and antiepileptic therapies. However, substantial heterogeneity was observed in AI methodologies, target outcomes, validation strategies, and reported performance metrics. Most studies were retrospective and single-centre, while external validation and assessment of clinically meaningful outcomes remained limited. CONCLUSIONS: AI-based approaches show promising potential for improving precision dosing of narrow therapeutic index drugs, particularly when integrating pharmacogenomic and clinical variables. Nevertheless, current evidence is limited by methodological heterogeneity, inconsistent reporting, and insufficient external validation. Further prospective multicentre studies evaluating real-world clinical outcomes are needed before widespread clinical implementation can be recommended.

English
Can artificial intelligence improve precision dosing? a systematic review of narrow therapeutic index drugs.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界